| Astatine-211: production and availability M R Zalutsky, M Pruszynski Current radiopharmaceuticals 4 (3), 177-185, 2011 | 181 | 2011 |
| 131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment M D'Huyvetter, J De Vos, C Xavier, M Pruszynski, YGJ Sterckx, S Massa, ... Clinical cancer research 23 (21), 6616-6628, 2017 | 144 | 2017 |
| Post-elution processing of 44Ti/44Sc generator-derived 44Sc for clinical application M Pruszyński, NS Loktionova, DV Filosofov, F Rösch Applied Radiation and Isotopes 68 (9), 1636-1641, 2010 | 121 | 2010 |
| Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Nuclear medicine and biology 40 (1), 52-59, 2013 | 113 | 2013 |
| Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer M Pruszynski, M D’Huyvetter, F Bruchertseifer, A Morgenstern, T Lahoutte Molecular Pharmaceutics 15 (4), 1457-1466, 2018 | 94 | 2018 |
| Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc M Pruszyński, A Majkowska-Pilip, NS Loktionova, E Eppard, F Roesch Applied Radiation and Isotopes 70 (6), 974-979, 2012 | 92 | 2012 |
| Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling M Pruszynski, E Koumarianou, G Vaidyanathan, H Revets, N Devoogdt, ... Journal of nuclear medicine 55 (4), 650-656, 2014 | 89 | 2014 |
| New measurement of excitation functions for (p, x) reactions on natMo with special regard to the formation of 95mTc, 96m+ gTc, 99mTc and 99Mo O Lebeda, M Pruszyński Applied Radiation and Isotopes 68 (12), 2355-2365, 2010 | 87 | 2010 |
| Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with 225Ac as a Perspective Tool for Combined α-Radioimmunotherapy and … E Cędrowska, M Pruszyński, W Gawęda, M Żuk, P Krysiński, ... Molecules 25 (5), 1025, 2020 | 74 | 2020 |
| Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer Ł Dziawer, A Majkowska-Pilip, D Gaweł, M Godlewska, M Pruszyński, ... Nanomaterials 9 (4), 632, 2019 | 74 | 2019 |
| Production and supply of α-particle–emitting radionuclides for targeted α-therapy V Radchenko, A Morgenstern, AR Jalilian, CF Ramogida, C Cutler, ... Journal of nuclear medicine 62 (11), 1495-1503, 2021 | 68 | 2021 |
| Radiolabeling and in vitro evaluation of 67Ga-NOTA-modular nanotransporter–A potential Auger electron emitting EGFR-targeted radiotherapeutic E Koumarianou, TA Slastnikova, M Pruszynski, AA Rosenkranz, ... Nuclear medicine and biology 41 (6), 441-449, 2014 | 64 | 2014 |
| Gold nanoparticle bioconjugates labelled with 211 At for targeted alpha therapy L Dziawer, P Koźmiński, S Męczyńska-Wielgosz, M Pruszyński, M Łyczko, ... RSC advances 7 (65), 41024-41032, 2017 | 53 | 2017 |
| Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy E Cędrowska, M Pruszynski, A Majkowska-Pilip, S Męczyńska-Wielgosz, ... Journal of Nanoparticle Research 20, 1-10, 2018 | 48 | 2018 |
| Preparation of Rh[16aneS4-diol]211At and Ir[16aneS4-diol]211At Complexes as Potential Precursors for Astatine Radiopharmaceuticals. Part I: Synthesis M Pruszynski, A Bilewicz, MR Zalutsky Bioconjugate chemistry 19 (4), 958-965, 2008 | 41 | 2008 |
| Adsorption of 137Cs on titanate nanostructures B Filipowicz, M Pruszyński, S Krajewski, A Bilewicz Journal of Radioanalytical and Nuclear Chemistry 301, 889-895, 2014 | 37 | 2014 |
| Trastuzumab-Modified Gold Nanoparticles Labeled with 211 At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer. A Majkowska-Pilip, D Gaweł, M Godlewska, M Pruszyński, J Jastrzębski, ... Nanomaterials 9 (4), 632, 2019 | 34 | 2019 |
| Trastuzumab modified barium ferrite magnetic nanoparticles labeled with radium-223: A new potential radiobioconjugate for alpha radioimmunotherapy W Gawęda, M Pruszyński, E Cędrowska, M Rodak, A Majkowska-Pilip, ... Nanomaterials 10 (10), 2067, 2020 | 30 | 2020 |
| 211At labeled substance P (5–11) as potential radiopharmaceutical for glioma treatment M Lyczko, M Pruszynski, A Majkowska-Pilip, K Lyczko, B Was, ... Nuclear Medicine and Biology 53, 1-8, 2017 | 26 | 2017 |
| N-Succinimidyl 3-((4-(4-[18 F] fluorobutyl)-1 H-1, 2, 3-triazol-1-yl) methyl)-5-(guanidinomethyl) benzoate ([18 F] SFBTMGMB): a residualizing label for 18 F-labeling of … G Vaidyanathan, D McDougald, J Choi, M Pruszynski, E Koumarianou, ... Organic & biomolecular chemistry 14 (4), 1261-1271, 2016 | 25 | 2016 |
